Delisting risk
Tivic Health Systems
Develops TLR5 immunotherapies and biomanufacturing services for radiation and oncology uses.
$0.2577
At close−0.03 (−10.46%)
| Date | Estimate | Reported | Surprise |
|---|---|---|---|
| Aug 2026 | −$408.00 | — | — |
| Apr 2026 | −$408.00 | −$2.23 | +99.5% |
| Mar 2026 | — | −$0.90 | — |
| Nov 2025 | — | −$1.97 | — |
| Aug 2025 | — | −$2.19 | — |
The latest year is open to everyone — the 21 quarters behind it read with an account. Sign in | |||
| May 2025 | |||
| Mar 2025 | |||
| Nov 2024 | |||
| Aug 2024 | |||
| May 2024 | |||
| Mar 2024 | |||
| Nov 2023 | |||
| Aug 2023 | |||
| Mar 2023 | |||
| Mar 2023 | |||
| Nov 2022 | |||
| Aug 2022 | |||
| May 2022 | |||
| Mar 2022 | |||
| Sep 2021 | |||
| Jun 2021 | |||
| Mar 2021 | |||
| Dec 2020 | |||
| Sep 2020 | |||
| Jun 2020 | |||
| Mar 2020 | |||
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise |
|---|---|---|---|---|---|---|
| Aug 17, 2026 | −$408.00 | — | — | $460.0K | — | — |
| Apr 1, 2026 | −$408.00 | −$2.23 | +99.5% | $460.0K | — | — |
| Mar 25, 2026 | — | −$0.90 | — | — | −$302.0K | — |
| Nov 14, 2025 | — | −$1.97 | — | — | $146.0K | — |
| Aug 14, 2025 | — | −$2.19 | — | — | $86.0K | — |
The latest year is open to everyone — the 21 quarters behind it read with an account. Sign in | ||||||
| May 15, 2025 | ||||||
| Mar 21, 2025 | ||||||
| Nov 14, 2024 | ||||||
| Aug 14, 2024 | ||||||
| May 15, 2024 | ||||||
| Mar 29, 2024 | ||||||
| Nov 14, 2023 | ||||||
| Aug 14, 2023 | ||||||
| Mar 31, 2023 | ||||||
| Mar 13, 2023 | ||||||
| Nov 14, 2022 | ||||||
| Aug 15, 2022 | ||||||
| May 16, 2022 | ||||||
| Mar 31, 2022 | ||||||
| Sep 30, 2021 | ||||||
| Jun 30, 2021 | ||||||
| Mar 31, 2021 | ||||||
| Dec 31, 2020 | ||||||
| Sep 30, 2020 | ||||||
| Jun 30, 2020 | ||||||
| Mar 31, 2020 | ||||||